Page 3 - Drug Manufacturers

Lupin introduces generic version of Zemuron Injection in United States

The newly introduced Rocuronium Bromide Injection is available in two formulations

Sanofi loses $21 bn in market value after dropping 2025 profit target

Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data

Drug regulatory reforms for improving quality

A strong drug regulation system is essential for India, as it not only supplies quality drugs to its own population but is responsible for meeting 20 per cent of the global demand

Zydus unit recalls 7,248 bottles of Oxybutynin Chloride tablets in US

A unit of Zydus Lifesciences is recalling over 7,000 bottles of Oxybutynin Chloride tablets in the US due to manufacturing issues, according to the US Food and Drug Administration (USFDA). As per its latest Enforcement Report, the US health regulator said the drugmaker is recalling 7,248 bottles of Oxybutynin Chloride extended-release tablets, used to treat overactive bladder and urinary conditions, in the US. New Jersey-based Zydus Pharmaceuticals (USA) Inc. is recalling the affected lot due to "Failed Dissolution Specifications", the USFDA stated. The lot was produced at Ahmedabad and distributed in the US by Zydus Pharmaceuticals (USA) Inc, the US health regulator stated. The drug firm initiated the Class II recall on September 21 this year. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse hea

Drug regulator CDSCO finds syrups made by Norris Medicines toxic: Report

The drug regulator for Gujarat state, where Norris is based, told Reuters that its factory had been closed

WHO's good manufacturing norms to be made compulsory for all drug firms

Only 2,000 of the 10,500 manufacturing units in the country have the World Health Organization's GMP certification

WHO warns of a spurious rare disease drug Defitelio floating in India

The WHO said that the genuine manufacturer of Defitelio has confirmed that the product referenced in the alert is falsified

Jhunjhunwala family-backed Concord Biotech gains 27% on market debut

The strong listing follows healthy demand for the shares of Gujarat-based bulk drug maker in its Rs 1,551-crore initial public offering (IPO)

Health ministry proposes separate post for medical devices controller

Specific provision for recall of drugs and devices; penal provisions for substandard drugs

A critical lapse in Jan Vishwas Bill

In seeking to make life easier for entrepreneurs, the proposed new law raises several questions on patient safety

Centre moots unified portal for drug regulation to build trust in quality

Move seeks to harmonise regulatory requirements at central and state level

Indian drugs regulators took action against 105 pharma firms, says minister

Indian drugs regulators have taken action against 105 pharmaceutical companies after a risk-based inspection and audit of manufacturing plants, the health minister said on Tuesday

Boehringer Ingelheim names Gagandeep Singh as head of India pharma biz

Drug firm Boehringer Ingelheim on Monday said it has appointed Gagandeep Singh as head of the pharma business vertical for the Indian market. The company has appointed Singh as Managing Director and Head of Human Pharma India with effect from July 10. He will also join the Board of Boehringer Ingelheim India, the company said in a statement. Boehringer Ingelheim has three business areas -- Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. "Gagandeep's passion for fostering a customer-focused culture and his experience across complex health ecosystems will be invaluable to the organisation as we continue to strengthen our strategic and sustainability commitment to India," Boehringer Ingelheim Regional Managing Director and Head of Human Pharma for India, Middle East, Turkey and Africa Mohammed Tawil noted. Singh joins Boehringer Ingelheim from AstraZeneca, where he was the Managing Director for India and Africa Cluster Head. He succeeds Vani Manja, who mov

Big pharma: Here's why India's drug industry needs a major overhaul

The latest drug recalls just add to a long line of scandals that have tainted the pharma sector of India

Bitter medicine for pharma regulation

The Gambian tragedy has raised uncomfortable questions about drug regulation in India. The Truth Pill is a depressing but eye-opening reality check of the regulatory landscape

CDSCO, states begin joint checks of drug-making units across India

Objective of drug regulation is to ensure safety, efficacy, and quality of drugs

Innovator drugs maintain market hold even after patent expiry, shows data

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up

Gland Pharma stock seen underperforming after acquiring France's Cenexi

Lack of near-term visibility on profitability for the core business is another concern about Indian firm

Zuventus first in world to launch aviptadil for ARDS commercially

Discovered in 1970, the drug was tested on severe Covid-19 patients on DCGI's direction